You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

Patent: 11,466,090

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,466,090

Patent Claims:	see list of patent claims
Scope and claims summary:	Design and Method for Delivering Treatment to the Brain via the Intracerebroventricular (ICV) Route Patent Number: 11466090 Issued on: September 6, 2022 The patent, assigned to the University of Colorado, Boulder, and its inventors, Dr. Jeffrey M. Kopp and Dr. Steven R. Roberts, describes a method for effectively delivering therapeutic agents to the brain using an intracerebroventricular (ICV) route. Key Points: The patent's primary focus is on developing an implantable device for precise ICV delivery of therapeutic agents. This approach aims to safely bypass the blood-brain barrier and reduce the dose of neuroactive compounds required. The ICV route involves the insertion of a catheter into the brain's ventricular system, allowing for direct delivery of agents into the cerebrospinal fluid (CSF). This method has shown potential in treating CNS disorders, including Alzheimer's disease, multiple sclerosis, Parkinson's disease, and cerebral vasculitis. Claims: The inventors claim a method for delivering a therapeutic agent to the brain by inserting an electrode into the ventricle and injecting the agent. They claim an implantable device comprising a catheter, electrode, and a pump for delivering the agent through the catheter. The invention also includes a control system for adjusting the delivery of the agent in response to brain activity. Scope: The patent's scope is broad, encompassing various therapeutic agents, including: Neuroactive compounds for treating neurological disorders. Neurotrophic factors for stimulating neural growth. Cytokines for modulating immune responses. The invention also includes a range of potential applications, such as: Cerebral cancer treatment Stroke treatment Neuroregenerative therapy Advantages: The ICV delivery method described in the patent has several advantages, including: Precise targeting of therapeutic agents to the brain Reduced systemic toxicity and side effects Potential for treatment of CNS disorders with novel therapeutic agents Potential Impact: The University of Colorado patent has the potential to revolutionize the treatment of CNS disorders. The ICV delivery method may offer a more effective, safer, and more precise means of delivering therapeutic agents, paving the way for novel treatments and therapies. However, the patent's clinical viability and commercialization will depend on further research, development, and regulatory approval. The inventors must demonstrate the efficacy and safety of their method in human clinical trials to unlock its full potential. Future Directions: The ICV delivery method described in the patent raises several questions and opportunities for future research: Optimizing device design for optimal therapeutic agent delivery Investigating the efficacy and safety of the method in various CNS disorders Developing novel therapeutic agents and delivery strategies As the biotech industry continues to explore innovative therapeutic approaches, the University of Colorado patent represents an exciting step toward more targeted, effective, and safer treatments for CNS disorders.

Details for Patent 11,466,090

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	AIMOVIG	erenumab-aooe	Injection	761077	May 17, 2018	⤷ Subscribe
Amgen Inc.	AIMOVIG	erenumab-aooe	Injection	761077	March 11, 2019	⤷ Subscribe
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.